Cargando…

Experimental Therapeutics for Challenging Clinical Care of a Patient with an Extremely Rare Homozygous APOC2 Mutation

BACKGROUND: Among many causes of hypertriglyceridemia (HTG), familial chylomicronemia syndrome (FCS) is a rare monogenic disorder that manifests as severe HTG and acute pancreatitis. Among the known causal genes for FCS, mutations in APOC2 only account for <2% of cases. Medical nutrition therapy...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ueda, Masako, Wolska, Anna, Burke, Frances M., Escobar, Maria, Walters, Laura, Lalic, Dusanka, Hegele, Robert A., Remaley, Alan T., Rader, Daniel J., Dunbar, Richard L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2020
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7149354/ https://www.ncbi.nlm.nih.gov/pubmed/32292609 http://dx.doi.org/10.1155/2020/1865489

Ejemplares similares

OR21-3 Familial Chylomicronemia Syndrome: Distinguishing the Rare Among the Common in Adults for Appropriate Management
por: Ueda, Masako, et al.
Publicado: (2019)

SAT-578 A Rare Case of Laboratory Hypertriglyceridemia: Glycerol Kinase Deficiency
por: Ueda, Masako, et al.
Publicado: (2020)

APOC3 Interference for Familial Chylomicronaemia Syndrome
por: Hegele, Robert A
Publicado: (2022)

SUN-593 Variants in Known Monogenic Causal Genes of Hypertriglyceridemia Are Not Major Contributors for Hypertriglyceridemia in Lipodystrophy Due to a LMNA Mutation
por: Ueda, Masako, et al.
Publicado: (2020)

Short hydrocarbon stapled ApoC2-mimetic peptides activate lipoprotein lipase and lower plasma triglycerides in mice
por: Sviridov, Denis, et al.
Publicado: (2023)

Apoc2 loss-of-function zebrafish mutant as a genetic model of hyperlipidemia
por: Liu, Chao, et al.
Publicado: (2015)

Successful Nutritional Intervention for an Infant with Abetalipoproteinemia: A Novel Modular Formula (AbetaMF)
por: Ueda, Masako, et al.
Publicado: (2021)

40 Years of the APOC Partnership
por: Roungou, Jean-Baptist, et al.
Publicado: (2015)

Ethnic differences in ApoC-III concentration and the risk of cardiovascular disease: No evidence for the cardioprotective role of rare/loss of function APOC3 variants in non-Europeans
por: Rout, Madhusmita, et al.
Publicado: (2022)

APOC3: Triglycerides do matter
por: Hassan, Mohamed
Publicado: (2014)

Associations of the APOC3 rs5128 polymorphism with plasma APOC3 and lipid levels: a meta-analysis
por: Song, Yongyan, et al.
Publicado: (2015)

A rare variant in APOC3 is associated with plasma triglyceride and VLDL levels in Europeans
por: Timpson, Nicholas J., et al.
Publicado: (2014)

Treatment of Homozygous Familial Hypercholesterolemia With Evinacumab
por: Jeraj, Natasha, et al.
Publicado: (2021)

Erratum: A rare variant in APOC3 is associated with plasma triglyceride and VLDL levels in Europeans
por: Timpson, Nicholas J., et al.
Publicado: (2015)

Frequency and phenotype consequence of APOC3 rare variants in patients with very low triglyceride levels
por: Crawford, Dana C., et al.
Publicado: (2018)

Managing the Fight against Onchocerciasis in Africa: APOC Experience
por: Fobi, Grace, et al.
Publicado: (2015)

APOC-III: a Gatekeeper in Controlling Triglyceride Metabolism
por: Giammanco, Antonina, et al.
Publicado: (2023)

AAV-Mediated ApoC2 Gene Therapy: Reversal of Severe Hypertriglyceridemia and Rescue of Neonatal Death in ApoC2-Deficient Hamsters
por: Yang, Chun, et al.
Publicado: (2020)

Association between the -455T>C promoter polymorphism of the APOC3 gene and the metabolic syndrome in a multi-ethnic sample
por: Pollex, Rebecca L, et al.
Publicado: (2007)

A rare functional cardioprotective APOC3 variant has risen in frequency in distinct population isolates
por: Tachmazidou, Ioanna, et al.
Publicado: (2013)

Treatment of Homozygous Familial Hypercholesterolemia With ANGPTL3 Inhibitor, Evinacumab
por: Shamsudeen, Isabel, et al.
Publicado: (2023)

APOC1 promotes the progression of osteosarcoma by binding to MTCH2
por: Li, Renjie, et al.
Publicado: (2023)

Metabolic Characterization of a Rare Genetic Variation Within APOC3 and Its Lipoprotein Lipase–Independent Effects
por: Drenos, Fotios, et al.
Publicado: (2016)

Use of Apolipoprotein B in the Era of Precision Medicine: Time for a Paradigm Change?
por: Cole, Justine, et al.
Publicado: (2023)

Sex differences in HDL ApoC-III in American Indian youth
por: Blackett, Piers R, et al.
Publicado: (2012)

The Roles of ApoC-III on the Metabolism of Triglyceride-Rich Lipoproteins in Humans
por: Borén, Jan, et al.
Publicado: (2020)

Apolipoprotein Mimetic Peptides: Potential New Therapies for Cardiovascular Diseases
por: Wolska, Anna, et al.
Publicado: (2021)

Dissociation Between APOC3 Variants, Hepatic Triglyceride Content and Insulin Resistance
por: Kozlitina, Julia, et al.
Publicado: (2011)

Investing in Onchocerciasis Control: Financial Management of the African Programme for Onchocerciasis Control (APOC)
por: Bundy, Donald A. P., et al.
Publicado: (2015)

APOC3 induces endothelial dysfunction through TNF-α and JAM-1
por: Tao, Yun, et al.
Publicado: (2016)

ApoC-III is a novel inducer of calcification in human aortic valves
por: Schlotter, Florian, et al.
Publicado: (2021)

ApoC3 is expressed in oocytes and increased expression is associated with PCOS progression
por: Zhou, Jiahe, et al.
Publicado: (2023)

OR24-02 Case Series Of Canadian Patients With Homozygous Familial Hypercholesterolemia Treated With ANGPTL3 Inhibitor Evinacumab
por: Shamsudeen, Isabel, et al.
Publicado: (2023)

APOC3 may not be a predictor of risk of ischemic vascular disease in the Chinese population
por: Tang, Liang, et al.
Publicado: (2014)

Deficient Cholesterol Esterification in Plasma of apoc2 Knockout Zebrafish and Familial Chylomicronemia Patients
por: Liu, Chao, et al.
Publicado: (2017)

A Novel APOC2 Mutation in a Colombian Patient with Recurrent Hypertriglyceridemic Pancreatitis
por: Pinilla-Monsalve, Gabriel D, et al.
Publicado: (2020)

Targeting ApoC3 Paradoxically Aggravates Atherosclerosis in Hamsters With Severe Refractory Hypercholesterolemia
por: Xu, Yitong, et al.
Publicado: (2022)

New Therapeutic Approaches to the Treatment of Dyslipidemia 1: ApoC-III and ANGPTL3
por: Kim, Ji Yoon, et al.
Publicado: (2023)

SUN-087 Effects of Leptin Replacement on Circulating Plasma Inhibitors of Lipoprotein Lipase in Patients with Lipodystrophy
por: Lightbourne, Marissa, et al.
Publicado: (2019)

Identification of Dysbetalipoproteinemia by an Enhanced Sampson-NIH Equation for Very Low-Density Lipoprotein-Cholesterol
por: Sampson, Maureen, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_2pjekgd425forjv97d7h6vb8jm